🟢 New in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒

🟢 New in Current Filing Failure to successfully realize cost savings from our restructuring initiatives would adversely impact our growth and profitability. 🔒

🟢 New in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒

🔴 No Match in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒

🔴 No Match in Current Filing Negative attention from special interest groups may impair our business. 🔒

🔴 No Match in Current Filing Contaminations in our animal populations can damage our inventory, harm our reputation for contaminant-free production, result in decreased sales and cause us to incur additional costs. 🔒

🔴 No Match in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒

🟡 Modified Impairment of long-lived tangible assets and intangible assets (such as goodwill and other intangible assets) may adversely impact future results of operations. 🔒

🟡 Modified A reduction or delay in government funding of R&D may adversely affect our business. 🔒

🟡 Modified Our by-laws designate the state courts located in the State of Delaware as the sole and exclusive forum for certain actions, including derivative actions, which could limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company and its directors, officers, other employees, or the Company's stockholders and may discourage lawsuits with respect to such claims. 🔒

🟡 Modified The outsourcing trend in non-clinical and clinical stages of drug discovery and development may decrease, which could impair our growth. 🔒

🟡 Modified The industries in which we operate are highly competitive. 🔒

🟡 Modified We have in the past experienced and in the future could experience unauthorized access into our information systems. 🔒

🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒

🟡 Modified We may not be able to successfully develop and market new services and products. 🔒

🟡 Modified Changes in government regulation or in practices relating to the pharmaceutical or biotechnology industries, including potential healthcare reform, could decrease the need for the services we provide. 🔒

🟡 Modified Failure to execute our business strategy could adversely impact our growth and profitability. 🔒

🟡 Modified Risk Factor Summary 🔒

🟡 Modified If we are unable to attract, hire or retain key team members or a highly skilled global workforce with various backgrounds and experiences, it could have a negative impact on our business, financial condition or results of operations. 🔒

🟡 Modified Our business is subject to risks relating to operating internationally, including changes in foreign currency exchange rates. 🔒

🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒

🟡 Modified Upgrading and integrating our business systems could result in implementation issues and business disruptions. 🔒

🟡 Modified Non-clinical and clinical contract research services create a risk of liability. 🔒

🟡 Modified Legal and Regulatory Risk Factors 🔒

🟡 Modified Negative attention from special interest groups may impair our business. 🔒

🟡 Modified We are required to comply with stringent, complex and evolving laws, rules, regulations and standards in many jurisdictions, as well as contractual obligations, relating to data privacy and security. Any actual or perceived failure to comply with these requirements could have a material adverse effect on our business. 🔒

🟡 Modified Contaminations in our animal populations can damage our inventory, harm our reputation for contaminant-free production, result in decreased sales and cause us to incur additional costs. 🔒

🟡 Modified If we are not successful in selecting and integrating the businesses and technologies we acquire or partner with, or if we do not manage our current and future site closures and divestitures, our business may be adversely impacted. 🔒

🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒

🟡 Modified CDMO services are highly complex and failure to provide quality and timely services to our CDMO customers, could adversely impact our business. 🔒

🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒